SBIR Phase I: Targeted Nanoparticle Delivery Agent for Treatment of Adult Leukemia

SBIR 第一阶段：用于治疗成人白血病的靶向纳米粒子递送剂

• 批准号: 1143342
• 负责人: Jon Nagy
• 金额: $ 14.98万
• 依托单位: NanoValent Pharmaceuticals, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1143342&HistoricalAwards=false
• 关键词: SBIR; Phase; Targeted; Nanoparticle; Delivery

This Small Business Innovation Research (SBIR) Phase I project aims to explore the application of a targeted nanodelivery system for both treatment and efficacy monitoring in patients with adult leukemia. Unlike solid tumors, for which surgery, radiation, and conventional treatments are an option, leukemias are cancers of the blood, which have very poor prognosis due to the fact that they are disseminated diseases from inception. In this project, the targeted and drug-filled nanoparticle will be optimized for effective tumor killing in cell culture, followed by validation using established in-vivo methods for adult leukemia in a mouse model. It is expected that this targeted nanodelivery system will increase the therapeutic window and minimize systemic therapy related toxicity, demonstrating the superior margin of safety compared to the standard methods for treatment.The broader/commercial impact of this project will be the potential to provide a technology that is capable of delivering a wide array of drug molecules (hydrophilic and hydrophobic) or drug cocktails using multiple tissue targeting ligands. The specific focus of this project is adult acute leukemia for which there is currently no curative treatment, and the adult survival rate is only 30%. Highly robust, customizable, stable, and easy to manufacture, this particle delivery system is anticipated to make a major impact on the treatment of adult leukemia.

这个小企业创新研究（SBIR）第一阶段项目旨在探索靶向纳米递送系统在成人白血病患者治疗和疗效监测中的应用。与实体瘤不同，手术，放射和常规治疗是一种选择，白血病是血液癌症，由于它们从一开始就是传播性疾病，因此预后非常差。在该项目中，靶向和药物填充的纳米颗粒将被优化，以在细胞培养中有效杀死肿瘤，然后使用已建立的小鼠模型中成人白血病的体内方法进行验证。 预期这种靶向纳米递送系统将增加治疗窗口并使全身治疗相关毒性最小化，证明了与标准治疗方法相比具有上级安全边际。该项目的更广泛/商业影响将是提供能够递送广泛药物分子的技术的潜力（亲水性和疏水性）或使用多个组织靶向配体的药物混合物。该项目的具体重点是成人急性白血病，目前尚无治愈性治疗方法，成人存活率仅为30%。 高度耐用，可定制，稳定，易于制造，这种颗粒输送系统预计将对成人白血病的治疗产生重大影响。